174 related articles for article (PubMed ID: 36104927)
1. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
4. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives.
Narjoz C; Nadour Z; Zaanan A; Taieb J; Loriot MA; Pallet N
Clin Chim Acta; 2023 Mar; 543():117326. PubMed ID: 37011867
[TBL] [Abstract][Full Text] [Related]
5. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
[TBL] [Abstract][Full Text] [Related]
6. Issues and limitations of available biomarkers for fluoropyrimidine-based chemotherapy toxicity, a narrative review of the literature.
Hodroj K; Barthelemy D; Lega JC; Grenet G; Gagnieu MC; Walter T; Guitton J; Payen-Gay L
ESMO Open; 2021 Jun; 6(3):100125. PubMed ID: 33895696
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Jacobs BA; Rosing H; de Vries N; Meulendijks D; Henricks LM; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2016 Jul; 126():75-82. PubMed ID: 27179185
[TBL] [Abstract][Full Text] [Related]
8. Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions.
van den Wildenberg SAH; Streng AS; van den Broek R; Broeren MAC; Deenen MJ; van Dongen JLJ; Hanrath MA; Lapré C; Brunsveld L; Scharnhorst V; van de Kerkhof D
J Pharm Biomed Anal; 2022 Nov; 221():115027. PubMed ID: 36099723
[TBL] [Abstract][Full Text] [Related]
9. Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Gaible C; Narjoz C; Loriot MA; Roueff S; Pallet N
Cancer Chemother Pharmacol; 2021 Dec; 88(6):1049-1053. PubMed ID: 34515833
[TBL] [Abstract][Full Text] [Related]
10. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
11. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
[TBL] [Abstract][Full Text] [Related]
12. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B; Launay M; Ciccolini J; Derain L; Parant F; Thomas F; Guitton J
ESMO Open; 2023 Jun; 8(3):101577. PubMed ID: 37267808
[TBL] [Abstract][Full Text] [Related]
13. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
de With M; Knikman J; de Man FM; Lunenburg CATC; Henricks LM; van Kuilenburg ABP; Maring JG; van Staveren MC; de Vries N; Rosing H; Beijnen JH; Pluim D; Modak A; Imholz ALT; van Schaik RHN; Schellens JHM; Gelderblom H; Cats A; Guchelaar HJ; Mathijssen RHJ; Swen JJ; Meulendijks D
Clin Pharmacol Ther; 2022 Jul; 112(1):62-68. PubMed ID: 35397172
[TBL] [Abstract][Full Text] [Related]
18. A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Marin C; Krache A; Palmaro C; Lucas M; Hilaire V; Ugdonne R; De Victor B; Quaranta S; Solas C; Lacarelle B; Ciccolini J
Clin Transl Sci; 2020 Jul; 13(4):761-768. PubMed ID: 32058656
[TBL] [Abstract][Full Text] [Related]
19. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C; Fonrose X; Thomas F; Roth G; Jacquet E; Brice A; Chirica C; Farneti D; Frenoux C; Stanke-Labesque F; Gautier-Veyret E
Br J Clin Pharmacol; 2023 Aug; 89(8):2446-2457. PubMed ID: 36918744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
